Blog

The MHRA has maintained that the benefits of GLP-1 medicines outweigh their potential risks when they are used appropriately and according to authorised indications. Experts say the UK figures therefore need to be interpreted in context. People taking these medicines may already have conditions such as diabetes, obesity, cardiovascular disease or kidney disease, which independently increase the risk of serious illness and death. At the same time, large clinical trials have demonstrated significant health benefits from GLP-1 drugs, including reductions in cardiovascular events and, in some populations, cardiovascular mortality.